Descrizione del progetto
Una nuova piattaforma di colture cellulari tridimensionali per sostituire gli animali nei test preclinici
Attualmente, oltre l’85 % degli studi clinici in fase iniziale fallisce nonostante i risultati promettenti dei test preclinici in vitro. Il motivo principale è attribuibile alle colture cellulari bidimensionali in vitro che non riproducono l’ambiente dell’organismo vivente. Di conseguenza, i test preclinici sugli animali rimangono un punto di riferimento, nonostante i costi correlati e le preoccupazioni etiche. L’azienda ceca InoCure sta sviluppando un’esclusiva piattaforma di impalcature tridimensionali per la coltura cellulare in vitro dotata di un sistema integrato per la somministrazione di farmaci. L’obiettivo è migliorare notevolmente l’efficienza della transizione dalla fase preclinica a quella clinica, fornendo al contempo un’alternativa ai modelli di test sugli animali. Il progetto DiffMATRIX, finanziato dall’UE, si propone di eseguire lo studio di fattibilità, valutando la fattibilità legale, economica e tecnica dell’introduzione della tecnologia sul mercato.
Obiettivo
The use of in-vitro testing (in simulated environment) is the future of drug development, cancer research and medical research in general since it overcomes the practical and ethical issues associated with human and animal experimentation. However, as much as 85% of early clinical trials currently fail despite successful preclinical in-vitro testing; in the case of clinical cancer trials it is less than 8%. The main reason for such low success rates is that currently used 2D cells do not behave the same in living bodies as in cultures. As a consequence, animal testing continues to be widespread despite the associated cost and strong ethical concerns it raises. This is also extremely costly in time and resources which raise consumer prices for life-saving medications.
InoCure is addressing this problem with the DifMATRIX - a unique 3D scaffolding platform with drug delivery embedded system, for cell culture used in molecular biology and tissue engineering. DifMATRIX enables to simulate natural cell phenotype (in vivo) in the in-vitro environment. It redefines in-vitro preclinical testing standards, significantly improving preclinical-to-clinical translation efficiency and provide an alternative to animal testing models. The predicted impact of the project is to eliminate the animal testing phase from the drug development process.
The project is well aligned with new trends in cell and tissue culture supplier market. Globally, this market is witnessing significant growth due to increasing demand for biopharmaceuticals and increasing R&D in this field. The global cell/tissue engineering supplies market is expected to reach $28 billion in 2020. The market demand for DifMATRIX has been confirmed by customers currently using our passive InoMATRIX product, and by the letters of intent from prospective customers.
Following the proposed Phase 1, Inocure target is to apply for the Phase 2 project to scale-up the production and launch commercialisation of DifMATRIX.
Campo scientifico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologytissue engineering
- medical and health sciencesclinical medicineoncology
- natural sciencesbiological sciencesmolecular biology
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEINST-1-2016-2017
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
11000 Praha
Cechia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.